Geneva Advisors’s Kite Pharma, Inc. KITE Stock Holding History

Geneva Advisors’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-17,165	Closed	-$1.35M	–	812
2017 Q1	$1.35M	Buy	+17,165	New	+$1.06M	0.02%	289
2015 Q2	–	Sell	-5,760	Closed	-$332K	–	718
2015 Q1	$332K	Buy	+5,760	New	+$386K	0.01%	497

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geneva Advisors's KITE Position: Q2 2017 in Review

Geneva Advisors sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 17,165 shares — an estimated $1.35M sold.

Geneva Advisors first reported a position in KITE in Q1 2015 and held it in 2 quarters. The position peaked at $1.35M in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

Geneva Advisors reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
Geneva Advisors sold 17,165 Kite Pharma, Inc. shares in Q2 2017, an estimated $1.35M.
Geneva Advisors first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 2 quarters.
Geneva Advisors's Kite Pharma, Inc. position peaked at $1.35M in Q1 2017.
220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.